In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 7, 2014, Pages 1465-1475

  Li, Jian ^a   Pant, Aakansha ^a   Chin, Chee Fei ^a   Ang, Wee Han ^a   Ménard Moyon, Cécilia ^b   Nayak, Tapas R ^a   Gibson, Dan ^c   Ramaprabhu, Sundara ^d   Panczyk, Tomasz ^e   Bianco, Alberto ^b   Pastorin, Giorgia ^a,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^e INSTITUTE OF CATALYSIS AND SURFACE CHEMISTRY   (Poland)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biodistribution; Carbon nanotubes; Drug delivery; Histopathology; Platinum based drugs

Indexed keywords

CARBON NANOTUBES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; HISTOLOGY; MAMMALS; MOLECULES; MULTIWALLED CARBON NANOTUBES (MWCN); NANOTUBES; TARGETED DRUG DELIVERY; TISSUE;

BIODISTRIBUTIONS; CHEMOTHERAPEUTIC DRUGS; DRUG DELIVERY SYSTEM; FUNCTIONALIZED CARBON NANOTUBES; FUNCTIONALIZED NANOTUBES; HISTOLOGICAL EVALUATION; HISTOPATHOLOGY; PLATINUM-BASED CHEMOTHERAPY;

PLATINUM COMPOUNDS;

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MULTI WALLED NANOTUBE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; DRUG CARRIER; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; TARGET ORGAN; TISSUE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; FEMALE; MICE; MICE, INBRED BALB C; NANOTUBES, CARBON; PLATINUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 84912150496     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.01.004     Document Type: Article

References (54)

1. Itamochi H., Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 2012, 17(5):430-440.
2. Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., Pujade-Lauraine E., et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012, 23(10):2605-2612.
3. Inal A., Kaplan M.A., Kucukoner M., Urakci Z., Karakus A., Isikdogan A. Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution. Asian Pac J Cancer Prev 2012, 13(5):1837-1840.
4. Crabb S.J., Bradbury J., Nolan L., Selman D., Muthuramalingam S.R., Cave J., et al. A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. Chemotherapy 2012, 58(4):257-263.
5. Fukui N., Kohno Y., Ishioka J., Fukuda H., Kageyama Y., Higashi Y. Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience. Int J Clin Oncol 2013, 18(4):731-734.
6. Gravalos C., Salut A., Garcia-Giron C., Garcia-Carbonero R., Leon A.I., Sevilla I., et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol 2012, 14(8):606-612.
7. Han J.S., Choi S.R., Jang J.S., Roh M.H., Kim D.C., Ryu S.H., et al. A case of synchronous esophagus and stomach cancer successfully treated by combined chemotherapy. Korean J Gastroenterol 2012, 60(2):113-118.
8. Rigacci L., Fabbri A., Puccini B., Chitarrelli I., Chiappella A., Vitolo U., et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 2010, 116(19):4573-4579.
9. Osawa T., Davies D., Hartley J.A. Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells. Cell Death Dis 2011, 2(8):e187.
10. Tamura T., Imai J., Matsumoto A., Tanimoto M., Suzuki A., Horikiri Y., et al. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm 2002, 54(1):1-7.
11. Sova P., Chladek J., Zak F., Mistr A., Kroutil A., Semerad M., et al. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. Int J Pharm 2005, 288(1):123-129.
12. Kido Y., Khokhar A.R., Siddik Z.H. Pharmacokinetics of intravenously injected [3H]tetrachloro(D, L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice. Drug Metab Dispos 1992, 20(5):673-678.
13. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008, 6(1):1-18.
14. Rybak L.P., Mukherjea D., Jajoo S., Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009, 219(3):177-186.
15. Steiner H., Scheiber K., Berger A.P., Rein P., Hobisch A., Aufderklamm J., et al. Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int 2011, 107(7):1074-1079.
16. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., et al. Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers. J Cancer Res Clin Oncol 2004, 130(12):741-744.
17. Ibrahim A., Hirschfeld S., Cohen M.H., Griebel D.J., Williams G.A., Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004, 9(1):8-12.
18. Cavanna L., Artioli F., Codignola C., Lazzaro A., Rizzi A., Gamboni A., et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 2006, 29(4):371-375.
19. Esquis P., Consolo D., Magnin G., Pointaire P., Moretto P., Ynsa M.D., et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 2006, 244(1):106-112.
20. Yang S.T., Wang X., Jia G., Gu Y.Q., Wang T.C., Nie H.Y., et al. Long-term accumulation and low toxicity of single-walled carbon nanotubes in intravenously exposed mice. Toxicol Lett 2008, 181(3):182-189.
21. Deng X., Yang S., Nie H., Wang H., Liu Y. A generally adoptable radiotracing method for tracking carbon nanotubes in animals. Nanotechnology 2008, 19(7):075101.
22. Lacerda L., Ali-Boucetta H., Herrero M.A., Pastorin G., Bianco A., Prato M., et al. Tissue histology and physiology following intravenous administration of different types of functionalized multiwalled carbon nanotubes. Nanomedicine (Lond) 2008, 3(2):149-161.
23. Singh R., Pantarotto D., Lacerda L., Pastorin G., Klumpp C., Prato M., et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A 2006, 103(9):3357-3362.
24. McDevitt M.R., Chattopadhyay D., Jaggi J.S., Finn R.D., Zanzonico P.B., Villa C., et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One 2007, 2(9):e907.
25. McDevitt M.R., Chattopadhyay D., Kappel B.J., Jaggi J.S., Schiffman S.R., Antczak C., et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007, 48(7):1180-1189.
26. Yang S.T., Fernando K.A., Liu J.H., Wang J., Sun H.F., Liu Y., et al. Covalently PEGylated carbon nanotubes with stealth character in vivo. Small 2008, 4(7):940-944.
27. Deng X., Jia G., Wang H., Sun H., Wang X., Yang S., et al. Translocation and fate of multi-walled carbon nanotubes in vivo. Carbon 2007, 45(7):1419-1424.
28. Yang S.T., Guo W., Lin Y., Deng X.Y., Wang H.F., Sun H.F., et al. Biodistribution of pristine single-walled carbon nanotubes in vivo. J Phys Chem C 2007, 111(48):17761-17764.
29. Liu Z., Davis C., Cai W., He L., Chen X., Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A 2008, 105(5):1410-1415.
30. Al-Jamal K.T., Nunes A., Methven L., Ali-Boucetta H., Li S., Toma F.M., et al. Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile. Angew Chem Int Ed Engl 2012, 51(26):6389-6393.
31. Li J., Yap S.Q., Yoong S.L., Nayak T.R., Chandra G.W., Ang W.H., et al. Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. Carbon 2012, 50(4):1625-1634.
32. Li J., Yap S.Q., Chin C.F., Tian Q., Yoong S.L., Pastorin G., et al. Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: selective release by chemical reduction and hydrophobicity reversal. Chem Sci 2012, 3(6):2083-2087.
33. Siddik Z.H., Jones M., Boxall F.E., Harrap K.R. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 1988, 21(1):19-24.
34. Scolaro C., Bergamo A., Brescacin L., Delfino R., Cocchietto M., Laurenczy G., et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 2005, 48(12):4161-4171.
35. Ajima K., Yudasaka M., Murakami T., Maigne A., Shiba K., Ijima S. Carbon nanohorns as anticancer drug carriers. Mol Pharm 2005, 2(6):475-480.
36. Ajima K., Yudasaka M., Maigne A., Miyawaki J., Iijima S. Effect of functional groups at hole edges on cisplatin release from inside single-wall carbon nanohorns. J Phys Chem B 2006, 110(11):5773-5778.
37. Tripisciano C., Kraemer K., Taylor A., Borowiak-Palen E. Single-wall carbon nanotubes based anticancer drug delivery system. Chem Phys Lett 2009, 478(4-6):200-205.
38. Guven A., Rusakova I.A., Lewis M.T., Wilson L.J. Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials 2012, 33(5):1455-1461.
39. Fraczek A., Menaszek E., Paluszkiewicz C., Blazewicz M. Comparative in vivo biocompatibility study of single- and multi-wall carbon nanotubes. Acta Biomater 2008, 4(6):1593-1602.
40. Sato Y., Yokoyama A., Shibata K., Akimoto Y., Ogino S., Nodasaka Y., et al. Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-I in vitro and subcutaneous tissue of rats in vivo. Mol Biosyst 2005, 1(2):176-182.
41. Qi W., Li Z., Bi J., Wang J., Sun T., Guo Y.A., et al. Biodistribution of co-exposure to multi-walled carbon nanotubes and nanodiamonds in mice. Nanoscale Res Lett 2012, 7(1):473.
42. Lam C.W., James J.T., McCluskey R., Arepalli S., Hunter R.L. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit Rev Toxicol 2006, 36(3):189-217.
43. Donaldson K., Aitken R., Tran L., Stone V., Duffin R., Forrest G., et al. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006, 92(1):5-22.
44. Shvedova A.A., Kisin E.R., Porter D., Schulte P., Kagan V.E., Fadeel B., et al. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?. Pharmacol Ther 2009, 121(2):192-204.
45. Teramoto K., Asada Y., Ozaki Y., Suzumura Y., Nakano Y., Sawai S., et al. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol 2012, 70(4):531-537.
46. Graham L.A., Suryadi J., West T.K., Kucera G.L., Bierbach U. Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. J Med Chem 2012, 55(17):7817-7827.
47. Kim E.S., Lee J.J., He G., Chow C.W., Fujimoto J., Kalhor N., et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 2012, 30(27):3345-3352.
48. Hozhenko A.I., Moskalenko O.M., Sirman V.M., ZhiZhnievs'ka O.O., Storozhenko S.A. Kidney function in oncologic patients after cisplastin chemotherapy. Fiziol Zh 2012, 58(3):72-76.
49. Junior A.D., Mota L.G., Nunan E.A., Wainstein A.J., Wainstein A.P., Leal A.S., et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007, 80(7):659-664.
50. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999, 43(1):1-7.
51. Kolosnjaj-Tabi J., Hartman K.B., Boudjemaa S., Ananta J.S., Morgant G., Szwarc H., et al. In vivo behavior of large doses of ultrashort and full-length single-walled carbon nanotubes after oral and intraperitoneal administration to Swiss mice. ACS Nano 2010, 4(3):1481-1492.
52. 4 hybrid MRI contrast agents. Biomaterials 2011, 32(21):4867-4876.
53. Andersen A.J., Wibroe P.P., Moghimi S.M. Perspectives on carbon nanotube-mediated adverse immune effects. Adv Drug Deliv Rev 2012, 64(15):1700-1705.
54. Jia G., Wang H.F., Yan L., Wang X., Pei R.J., Yan T., et al. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol 2005, 39(5):1378-1383.